Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1714567

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on the availability of Creon 25000 across the UK.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	24095
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24096 question first answered 01/05/2024 16:00:34 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4640 label Biography information for David Linden

1714568

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Shortages
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) mitigate potential future shortages of (i) Creon 25000 and (ii) other essential medicines and (b) ensure that people affected by medicine shortages have access to alternative options.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	24096
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24095 question first answered 01/05/2024 16:00:34 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4640 label Biography information for David Linden

1714664

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prosthetics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 April 2024 to Question 21490 on Prosthetics, if her Department will make an assessment of the potential merits of updating the stock of prosthetic limbs available.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	24158
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The NHS Supply Chain framework for prosthetic componentry will be subject to its next routine procurement exercise in the autumn of 2024, with contracts awarded to commence on 1 April 2025. This does not preclude devices currently not on the framework from being prescribed by prosthetic centres as they are able to order directly from the manufacturer, and report via the exceptions log managed by NHS Supply Chain.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:18:45 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4811 label Biography information for Navendu Mishra

1714667

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.64 of the NHS Long Term Plan, published in January 2019, what steps she is taking to ensure that every person diagnosed with cancer will have access to (a) personalised care, (b) a needs assessment, (c) a care plan and (d) health and wellbeing information and support.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	24159
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>Ensuring every person diagnosed with cancer has access to personalised care and support is a key priority for the Government. The NHS Long Term Plan for cancer states that where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. NHS England is committed to ensuring that all cancer patients have access to a Holistic Needs Assessment and Personalised Care and Support Planning, ensuring care is focused on what matters most to each person. Additionally, End of Treatment Summaries are being introduced, which aims to empower people to manage the impact of their cancer after treatment. Health and wellbeing information and support is provided from diagnosis onwards, and includes access to NHS Talking Therapy services for anxiety and depression. This is alongside wider work to improve psychosocial support for people affected by cancer, such as through local partnerships with cancer support charities.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring that the healthcare needs of local communities in England are met, including for cancer patients. NHS England provides access to a personal health budget, which is an amount of National Health Service money that is allocated to support the health and wellbeing needs of a patient, if eligible. Further information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:25:47 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4811 label Biography information for Navendu Mishra

1714677

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Databases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 April 2024 to Question 23065 on NHS: Databases, if he will hold discussions with the Federation of Clinical Registries on the (a) procurement and (b) centralising of clinical registries by the Medical Devices Outcome Registry programme.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	24161
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>NHS England’s Patient Outcomes and Registries Programme is not centralising all clinical registries. The programme is: providing a new, improved national approach to NHS England funded clinical registries that optimises the security and use of patient data to improve patient safety vigilance and to improve patient outcomes, innovation, and value; and expanding the coverage of NHS England’s clinical registries and patient reported outcome measurement into new areas, to meet the independent Cumberlege and Paterson enquiry requirements to improve patient outcomes. The programme is undertaking extensive engagement, and we propose that any meetings with specific stakeholder groups about the programme are organised via the Medical Devices Outcome Registry Programme Director.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:30:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4811 label Biography information for Navendu Mishra

1714690

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services and Social Services: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to improve recruitment and retention to deliver her Department's integrated one workforce approach.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	24070
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff. The plan recommends that integrated care boards (ICBs) and wider system partners prioritise actions that drive recruitment and retention of multi-disciplinary teams, in a one workforce approach.</p><p>There are a number of key national programmes aimed at supporting regions, ICBs, and providers with recruitment challenges, in growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment by encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.</p><p>The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICSs), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, and thereby reduce the NHS staff leaver rates.</p><p> </p><p>Support for organisations and ICSs can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies to enable improvements and contact details for regional colleagues support the retention agenda in each of the seven regions. Further information is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/" target="_blank">https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:13:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1714693

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people have taken the accredited NHS Strategic Workforce Planning course through the Chartered Institute of Professional Development.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	24071
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:16:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1714695

registered interest
date	29/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Certification
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the number of clinicians who started advanced practice pathways in 2023-24.
tabling member constituency	Bristol South
tabling member printed	Karin Smyth
uin	24072
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:17:16 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4444 label Biography information for Karin Smyth

1714027

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sipavibart
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23829
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1714079

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23890
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.</p><p>The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:02:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell